靶向DMARDs治疗活动性银屑病关节炎诱导期的疗效与安全性比较:系统评价与网络Meta分析
该系统评价与网络Meta分析纳入29项RCT共10204例活动性PsA患者,比较17种靶向DMARDs在诱导期(12-16周)的疗效与安全性。结果显示除clazakizumab外所有治疗在ACR20和PASI75上均优于安慰剂,英夫利西单抗、古塞奇尤单抗、阿达木单抗、戈利木单抗、司库奇尤单抗和乌司奴单抗兼具较高疗效与安全性。
要点
- 除clazakizumab外,所有靶向DMARDs在ACR20和PASI75上均优于安慰剂。
- 英夫利西单抗、古塞奇尤单抗、阿达木单抗、戈利木单抗、司库奇尤单抗300mg在ACR20和PASI75上表现突出。
- 托法替布、阿普米司特和ixekizumab 80mg每2周不良事件率较高,但严重不良事件无显著差异。
核心结论
- 综合风险-获益特征,英夫利西单抗、古塞奇尤单抗、阿达木单抗、戈利木单抗、司库奇尤单抗和乌司奴单抗可能较其他靶向DMARDs在活动性PsA诱导期更安全有效。
研究设计与样本
- 系统文献综述纳入29项评估靶向合成DMARDs和生物DMARDs的随机对照试验,共10204例参与者、17种治疗。
- 采用随机效应模型进行传统Meta分析和网络Meta分析,估计合并OR及95%CI,并按ACR20、PASI75、AE和SAE进行比较和排序。
- 在生物制剂初治和生物制剂经治/失败人群中进行了类似分析。
主要发现
- 诱导期(前12-16周),除clazakizumab外所有治疗在ACR20和PASI75上均优于安慰剂。
- 托法替布、阿普米司特和ixekizumab 80mg每2周不良事件率较高,但所有治疗间SAE无显著差异。
- 网络Meta分析显示英夫利西单抗、戈利木单抗、依那西普、阿达木单抗、古塞奇尤单抗和司库奇尤单抗300mg在同时达到ACR20和PASI75上优于其他药物。
- 英夫利西单抗、古塞奇尤单抗、阿达木单抗、戈利木单抗、司库奇尤单抗(300mg和150mg)和乌司奴单抗(45mg和90mg)兼具高疗效和安全性。
- 生物制剂初治人群分析中排序相似;生物制剂经治/失败人群中,乌司奴单抗、司库奇尤单抗(300mg和150mg)、ixekizumab、阿巴西普、培塞利珠单抗、托法替布和阿普米司特仍与较安慰剂更高的ACR20相关,乌司奴单抗、司库奇尤单抗300mg、ixekizumab和托法替布与更高PASI75相关。
关键数值与推荐
- ACR20应答:除clazakizumab外所有治疗优于安慰剂。
- PASI75应答:除clazakizumab外所有治疗优于安慰剂。
- SAE:所有治疗间无显著差异。
- 不良事件率较高:托法替布、阿普米司特、ixekizumab 80mg每2周。
临床怎么用
- 对于活动性PsA诱导期治疗,可优先考虑英夫利西单抗、古塞奇尤单抗、阿达木单抗、戈利木单抗、司库奇尤单抗和乌司奴单抗等兼具疗效与安全性的靶向DMARDs。
- 生物制剂经治/失败患者中,乌司奴单抗、司库奇尤单抗、ixekizumab、阿巴西普、培塞利珠单抗、托法替布和阿普米司特仍显示优于安慰剂的ACR20应答。
- 选择治疗时需结合患者生物制剂暴露史及药物不良事件特征个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To summarize and investigate the comparative efficacy and safety of targeted disease-modifying antirheumatic drugs (DMARDs) for active psoriatic arthritis (PsA). METHODS: Randomized clinical trials (RCTs) evaluating efficacy and safety of targeted synthetic DMARDs (tofacitinib, apremilast) as well as biological DMARDs (guselkumab, ustekinumab, secukinumab, ixekizumab, brodalumab, clazakizumab, abatacept, adalimumab, etanercept, infliximab, certolizumab, and golimumab) were identified by systemic literature review. Traditional meta-analysis and network meta-analysis using a random effects model were performed to estimate pooled odds ratios (OR) and 95% CI to compare and rank these treatments according to ACR20 response, 75% improvement in psoriasis area and severity index (PASI75), numbers of adverse events (AE) and serious adverse events (SAE). Similar analyses were conducted among biologic-naïve population and biologic-experienced/failed population. RESULTS: We deemed 29 RCTs eligible, including 10,204 participants and 17 treatments. During induction therapy (first 12-16 weeks), all treatments except clazakizumab were more efficacious than placebo in achieving ACR20 and PASI75. Although tofacitinib, apremilast, and ixekinumab 80 mg every 2 weeks had a higher rate of AE, no significant difference was revealed for SAE among all treatments. Network meta-analysis demonstrated that infliximab, golimumab, etanercept, adalimumab, guselkumab, and secukinumab 300 mg outperformed other drugs in achieving both ACR20 and PASI75. Infliximab, guselkumab, adalimumab, golimumab, secukinumab (300 mg and 150 mg), and ustekinumab (45 mg and 90 mg) are characterized by both high efficacy and safety. Similar rankings were observed in the analysis among biologic-naïve patients. Moreover, ustekinumab, secukinumab (300 mg and 150 mg), ixekizumab, abatacept, certolizumab pegol, tofacitinib, and apremilast were still associated with higher ACR20 compared to placebo while ustekinumab, secukinumab (300 mg), ixekizumab and tofacitinib with higher PASI75 among biologic-experienced/failed patients. CONCLUSION: Regarding the overall risk-benefit profile, infliximab, guselkumab, adalimumab, golimumab, secukinumab, and ustekinumab may be safer and more efficacious treatments than the other targeted DMARDs for active PsA during induction therapy.
引用
- Lu C, Wallace BI, Waljee AK, et al. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis. Semin Arthritis Rheum. 2019. PMID: 31272807. doi:10.1016/j.semarthrit.2019.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。